Silo Pharma Inc.

Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions. They specialize in both traditional and psychedelic formulations, aiming to create innovative solutions for ailments like PTSD, stress-induced psychiatric disorders, chronic pain, and CNS diseases. Silo Pharma's strategy involves licensing and funding research from leading universities and researchers, allowing them to leverage existing intellectual property and utilize a streamlined 505(b)(2) regulatory pathway for faster and more cost-effective drug approvals.

The company has a growing pipeline of promising therapeutics, including SPC-15, an intranasal formulation for PTSD and stress-induced anxiety, and SP-26, a ketamine-based implant for chronic pain and fibromyalgia. Silo Pharma also has preclinical programs for Alzheimer's disease (SPC-14) and CNS disorders (SPU-16). Their commitment to scientific research and their focus on addressing unmet medical needs positions Silo Pharma as a potential leader in the future of therapeutic development.

Silo Pharma Inc. is a biopharmaceutical company focused on developing innovative treatments for underserved conditions, including PTSD, stress-induced psychiatric disorders, chronic pain, and CNS diseases. The company leverages both traditional pharmaceuticals and psychedelic medicine, licensing and funding research with the goal of developing transformative therapies that improve patient well-being and advance the healthcare industry.

Silo Pharma promotes a culture of innovation and collaboration, focused on developing novel therapeutics to address underserved conditions. They prioritize scientific rigor and partnering with leading academic institutions, while also maintaining a strong focus on patient well-being and improving healthcare outcomes. Their website emphasizes transparency and communication with investors, suggesting a commitment to open dialogue and ethical business practices.